The Pharma Data

JANUARY 12, 2021

Department of Health and Human Services (HHS) and the Department of Defense (DOD) will purchase additional supply of the casirivimab and imdevimab antibody cocktail for use in non-hospitalized COVID-19 patients to meet the federal government’s Operation Warp Speed goals. million doses. . We are pleased to work with the U.S.

Government 52

Government Hospitals Virus Clinical Trials 52

Agency IQ

JANUARY 26, 2024

Such a situation is commonplace in the clinical trial realm, in which investigational drug products which are not already FDA approved are administered to patients. Under the Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 (PAHPRA) , the FDA also has some authority to extend MCM expiration dates.

Science 40

Science FDA Production Packaging 40

The Pharma Data

JANUARY 6, 2021

The approval in India is an important milestone as it will enable to supply India but also a large number of countries around the world. AZD1222 (SARS-CoV-2 vaccine) FDA Approval History. COVID-19 Vaccine AstraZeneca, formerly AZD1222 AZD1222 was co-invented by the University of Oxford and its spin-out company, Vaccitech.

Vaccine 52

Vaccine Virus Clinical Trials Government 52

The Pharma Data

FEBRUARY 25, 2022

Pfizer is a leader in this vital healthcare segment with more than 14 years of global in-market experience, the first FDA approved biosimilar for the treatment of certain autoimmune conditions and nine approved biosimilars in the U.S. For more than 170 years, we have worked to make a difference for all who rely on us.

Biosimilars 52

Biosimilars FDA FDA Approval Small Molecule 52

The Pharma Data

NOVEMBER 20, 2020

Even with these incredible efforts, demand may exceed supply initially, making it even more critical that federal and state governments ensure the casirivimab and imdevimab antibody cocktail is distributed fairly and equitably to the patients most in need. Casirivimab and imdevimab injection is not FDA approved for any use.

Therapies 52

Therapies FDA Clinical Trials Hospitals 52

Agency IQ

OCTOBER 6, 2023

AgencyIQ compiled these data using information in approval letters and review packages posted to the Drugs@FDA database. government fiscal year runs from October 1 – September 30. Despite the growing controversy, the number of products granted accelerated approval increased in FY 2023. As a reminder, the U.S.

FDA 52

FDA Biosimilars Science Drugs 52

The Pharma Data

AUGUST 6, 2020

See “Worldwide Pro Forma Revenue” in Quarterly Package of Financial Information for this quarter, which is available on bms.com/investors/financial-reporting/quarterly-results, for information on the revenue of the company and Celgene on a stand-alone basis for the prior-year period. Oncology and Hematology. Regulatory. Regulatory.

Production 52

Production International Licensing Licensing 52

The Pharma Data

NOVEMBER 21, 2020

government allocation program. Even with these incredible efforts, demand may exceed supply initially, making it even more critical that federal and state governments ensure REGEN-COV2 is distributed fairly and equitably to the patients most in need. government and Regeneron signed an agreement for this initial supply of REGEN-COV2.

FDA 40

FDA Clinical Trials Hospitals Production 40

The Pharma Data

NOVEMBER 5, 2020

FDA accepted for priority review Libtayo ® (cemiplimab-rwlc) for both advanced non-small cell lung cancer and basal cell carcinoma. FDA approved Inmazeb for Ebola ( Zaire ebolavirus). government. REGN-COV2 trial in the COVID-19 outpatient setting met primary and key secondary endpoints. Regeneron Pharmaceuticals, Inc.

Production 40

Production FDA Trials FDA Approval 40

Agency IQ

OCTOBER 27, 2023

While the FDA previously published a similar version of this document, Congress gave FDA new authority to require these plans. Government shutdown: At present, the U.S. federal government has appropriated funding through November 17. the drug and device) of the combination product.

FDA 40

FDA Science Regulations Production 40

Agency IQ

JUNE 16, 2023

The proposed rule will identify certain bulk drug substances that FDA has considered and is proposing to place on the 503A Bulks List and certain bulk drug substances that FDA has considered and is proposing not to include on the 503A Bulks List. Repeal of this regulation would eliminate an unnecessary policy.

Regulations 40

Regulations FDA Science Production 40

The Pharma Data

NOVEMBER 30, 2020

Additionally, Moderna announced that the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting to review the safety and efficacy data package for mRNA-1273 will likely be scheduled for Thursday, December 17. government has agreed to provide up to $1.525 billion to purchase supply of mRNA-1273 under U.S.

Vaccine 52

Vaccine FDA Clinical Trials Disease 52

The Pharma Data

DECEMBER 29, 2020

government, Regeneron is producing approximately 300,000 doses (2,400 mg) for outpatient use under the EUA. government regarding additional doses. . Casirivimab and imdevimab injection is not FDA approved for any use. Under an agreement with the U.S. In the U.S.

Hospitals 52

Hospitals Trials Clinical Trials Production 52

The Pharma Data

JANUARY 9, 2021

This growth primarily reflects increased sales of contract development and manufacturing (CDMO) services to pharmaceutical and biotechnology innovators and government/non-government organization (NGO) customers, as well as higher product sales. Other 2021 Assumptions. FOOTNOTES. (1)

Government 40

Government Vaccine Production Licensing 40

Agency IQ

JANUARY 12, 2024

After lengthy review, FDA approves Florida’s drug importation plan After a years-long review process, the FDA today announced its approval of Florida’s proposal to import certain prescription drug products from Canada. Drug labeling : Labeling for the imported drug product must be consistent with the current required U.S.

FDA Approval 40

FDA Approval FDA Science Drugs 40

Agency IQ

MARCH 7, 2024

BY LAURA DIANGELO, MPH | MAR 6, 2024 5:54 PM CST Fiscal year 2024 appropriations bills On March 3, 2024, House and Senate appropriators released a package of final fiscal year (FY) 2024 appropriations bills. The new bill is intended to serve as the FY2024 appropriations, and stave off a shutdown of government operations.

FDA 40

FDA Packaging Science Drugs 40

Agency IQ

NOVEMBER 3, 2023

So what about all of the “biotic” terms that pop up in the news, on products labels and even in FDA warning letters? Unfortunately, there is no regulatory body that governs the terminology used in this space, although there are definitions that are generally accepted by the scientific community.

Therapies 40

Therapies Science FDA Production 40

The Pharma Data

OCTOBER 14, 2020

Food and Drug Administration (FDA) approved Inmazeb (atoltivimab, maftivimab and odesivimab-ebgn) for the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including newborns of mothers who have tested positive for the infection. TARRYTOWN, N.Y., NASDAQ: REGN) announced today that the U.S.

FDA Approval 52

FDA Approval FDA Production Treatment 52

Agency IQ

DECEMBER 1, 2023

While the FDA previously published a similar version of this document, Congress gave FDA new authority to require these plans. Government shutdown: At present, the FDA has appropriated funding through January 19. Expect nearly every company to be closely reading this document when it’s eventually published.

FDA 40

FDA Science Regulations Production 40

The Pharma Data

JUNE 18, 2021

FDA approval for adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. RINVOQ ® (upadacitinib) [Package Insert]. 14 In August 2019 , RINVOQ received U.S. ClinicalTrials.gov. Accessed on April 20, 2021. North Chicago, Ill. AbbVie Inc. .

Treatment 40

Treatment Disease FDA Therapies 40

The Pharma Data

JUNE 18, 2021

IMBRUVICA is the only FDA-approved medicine in WM and cGVHD. IMBRUVICA was one of the first medicines to receive FDA approval via the Breakthrough Therapy Designation pathway. 8 VENCLEXTA (venetoclax) [Package Insert].?North?Chicago, BTK signaling is needed by specific cancer cells to multiply and spread.

Treatment 52

Treatment Therapies FDA FDA Approval 52

The Pharma Data

JUNE 18, 2021

IMBRUVICA is the only FDA-approved medicine in WM and cGVHD. IMBRUVICA was one of the first medicines to receive FDA approval via the Breakthrough Therapy Designation pathway. 9 VENCLEXTA (venetoclax) [Package Insert].?North BTK signaling is needed by specific cancer cells to multiply and spread. 8 IMBRUVICA U.S.

Treatment 40

Treatment FDA Therapies FDA Approval 40

The Pharma Data

MAY 5, 2021

FDA approves 100th monoclonal antibody product ( Nature Reviews Drug Discovery ). AI, digital health feature in latest batch of FDA breakthrough device designations ( MedTech Dive ). BD Taps Contract Packager for COVID-19 Test Kits ( MD+DI ). Government & Regulatory.

Vaccine 52

Vaccine FDA FDA Approval International 52

Drug & Device Law

DECEMBER 29, 2023

2023) (federal government may unilaterally obtain dismissal of FCA claims, and calling the constitutionality of the FCA’s private enforcement mechanism into question) ( here ); Quishenberry v. The FDA requires real science for warnings; thus it had not mandated any warning remotely resembling Prop 65. Polansky v. 3d 239 (Cal.

Testimonials 105

Testimonials Drugs FDA Vaccine 105

Drug & Device Law

NOVEMBER 1, 2022

In Arizona, a manufacturer is not liable for punitive damages when “[t]he product alleged to have caused the harm was designed, manufactured, packaged, labeled, sold or represented in relevant and material respects according to the terms of an approval, conditional approval, clearance, license or similar determination of a government agency.”

Testimonials 59

Testimonials FDA FDA Approval Packaging 59

FDA Law Blog: Biosimilars

JULY 10, 2025

Together, these laws signal a significant shift in how state governments may begin to challenge the status quo on food transparency, consumer rights, and ingredient safety. This labeling requirement will apply to packages “developed or copyrighted” from January 1, 2027 onward. Here’s what industry needs to know.

Packaging 66

Packaging Regulations FDA Production 66

LifeSciVC

MAY 28, 2025

Further, the pace of fast follower drugs is striking relative the past: according to PhRMAs recent report on innovation , the average time for a drug class to have three FDA approvals in it went from ~15 years in 1990-2003 to ~2 years in 2013-2021. No crowd, no drugs. May the best companies with the most successful drugs win.

Production 76

Production Marketing DNA Drugs 76

Codon

FEBRUARY 23, 2025

government issued a limited waiver that let PEPFAR resume HIV treatments abroad, pending further guidance. At a time when government HIV initiatives look uncertain, lenacapavir could prove a much-needed failsafe. By 1987, the FDA licensed zidovudine after trials showed it increased survival rates. By February, the U.S.

Clinical Trials 82

Clinical Trials Virus Vaccine DNA 82